Ensartinib hydrochloride - Generic Drug Details

What are the generic sources for ensartinib hydrochloride and what is the scope of freedom to operate?

Ensartinib hydrochloride is the generic ingredient in one branded drug marketed by Xcovery and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ensartinib hydrochloride has sixty-seven patent family members in twenty-one countries.

One supplier is listed for this compound.

Summary for ensartinib hydrochloride

International Patents:	67
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	35
Patent Applications:	16
DailyMed Link:	ensartinib hydrochloride at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ensartinib hydrochloride

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ensartinib hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tang-Du Hospital	PHASE1
The First Affiliated Hospital of Guangzhou Medical University	PHASE3
Shanghai Pulmonary Hospital, Shanghai, China	PHASE2

See all ensartinib hydrochloride clinical trials

US Patents and Regulatory Information for ensartinib hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xcovery	ENSACOVE	ensartinib hydrochloride	CAPSULE;ORAL	218171-001	Dec 18, 2024		RX	Yes	No
Xcovery	ENSACOVE	ensartinib hydrochloride	CAPSULE;ORAL	218171-001	Dec 18, 2024		RX	Yes	No	10,899,744			Y
Xcovery	ENSACOVE	ensartinib hydrochloride	CAPSULE;ORAL	218171-002	Dec 18, 2024		RX	Yes	Yes	9,296,724			Y
Xcovery	ENSACOVE	ensartinib hydrochloride	CAPSULE;ORAL	218171-002	Dec 18, 2024		RX	Yes	Yes	10,899,744			Y
Xcovery	ENSACOVE	ensartinib hydrochloride	CAPSULE;ORAL	218171-001	Dec 18, 2024		RX	Yes	No	9,126,947			Y

International Patents for ensartinib hydrochloride

Country	Patent Number	Title	Estimated Expiration
Japan	2016216475	置換ピリダジンカルボキサミド化合物 (SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS)
Hong Kong	1137295	激酶抑製劑化合物 (KINASE INHIBITOR COMPOUNDS)
Japan	5670325
Spain	2670665
World Intellectual Property Organization (WIPO)	2009154769

Ensartinib Hydrochloride: Market Dynamics and Financial Trajectory

Last updated: February 16, 2026

Market Overview and Approved Indications

Ensartinib hydrochloride is an experimental selective ALK (anaplastic lymphoma kinase) inhibitor developed for treating ALK-positive non-small cell lung cancer (NSCLC). It is part of a broader class of targeted therapies addressing specific genetic alterations in lung cancer.

It is not yet approved for commercial use globally. The drug primarily advances through clinical trials conducted by its developer, SpringWorks Therapeutics. Pending regulatory approval, its commercial potential hinges on efficacy data, safety profile, and positioning against competitors like alectinib, brigatinib, and lorlatinib.

Current Development Status

As of early 2023, ensartinib is in Phase II and III clinical trials. The key studies include:

• Phase III trial (e.g., eXalt3) comparing ensartinib with crizotinib in untreated ALK-positive NSCLC.
• Evaluation of efficacy metrics like progression-free survival (PFS), overall response rate (ORR), and duration of response.

Results showed promising efficacy, with median PFS exceeding 20 months in some cohorts, comparable or superior to existing therapies, and manageable safety profiles.

Market Size and Potential Revenue Streams

The global NSCLC market surpasses $20 billion annually and is projected to grow. ALK-positive NSCLC accounts for approximately 3-5% of NSCLC cases, equivalent to 600,000–1 million new cases annually.

Assuming ensartinib captures 15-20% of newly diagnosed ALK-positive NSCLC post-approval, it could generate peak annual revenues of approximately $300-600 million based on drug penetration, pricing strategies, and competition.

Pricing Strategies and Reimbursement Outlook

Pricing in oncology therapies ranges from $10,000 to $15,000 per month. Given the competitive landscape, ensartinib may price within this range, influenced by its comparative efficacy and safety. Reimbursement depends on regulatory approval, health technology assessments, and payer negotiations in target markets like the U.S., Europe, and Asia.

Competitive Landscape

Currently, approved ALK inhibitors include:

• Alectinib (Alecensa): $11,000–$13,000/month
• Brigatinib (Alunbrig): ~$10,000/month
• Lorlatinib (Lorbrena): ~$13,000/month

Ensartinib’s potential market share depends on trial outcomes and post-approval positioning. If it demonstrates superior efficacy or safety, it could displace or supplement existing options.

Regulatory and Commercial Timeline

• 2022-2023: Completion of pivotal trials
• Late 2023 - 2024: Anticipated NDA submissions (FDA, EMA)
• 2024-2025: Potential approval and market entry

Market penetration will depend on regulatory clearance timelines, manufacturing capacity, and strategic partnering.

Financial Trajectory and Investment Outlook

For the developer, assets in late-stage trials typically reflect valuation based on clinical data and potential market size. A successful Phase III readout can lead to:

• License or partnership deals with leading pharmaceutical firms
• Upfront payments and milestone bonuses exceeding hundreds of millions
• Royalty streams based on sales post-approval

In the absence of a marketed product, revenue forecasts are speculative. However, peer comparisons suggest peak sales could reach $300-600 million annually if approved and adequately positioned.

Risks and Challenges

• Regulatory hurdles in gaining approval based on trial results.
• Competitive pressure from established ALK inhibitors.
• Pricing and reimbursement negotiations to ensure market access.
• Clinical risks such as safety concerns or inferior efficacy.

Summary

Ensartinib hydrochloride remains an investigational asset with potential to address a niche within the large NSCLC market. Its ultimate financial trajectory depends heavily on clinical trial outcomes, regulatory decisions, and market dynamics. If approved, it could generate significant revenue streams in a competitive landscape with existing effective treatments.

---

Key Takeaways

• Ensartinib is in late-stage clinical development for ALK-positive NSCLC, with promising efficacy data.
• The targeted market could generate $300-600 million annually if approved and adopted.
• Competition from existing ALK inhibitors remains intense, affecting market share potential.
• Pricing likely in the $10,000–$15,000/month range, with reimbursement heavily dependent on clinical data and regulatory approval.
• Success hinges on positive trial results, regulatory clearance, and effective market positioning.

---

FAQs

1. When might ensartinib hydrochloride receive regulatory approval?
Approval could occur between late 2023 and 2025, contingent upon successful Phase III trial outcomes and regulatory review timelines.

2. How does ensartinib compare with existing ALK inhibitors?
Preliminary data suggests comparable or superior efficacy with a favorable safety profile. Direct head-to-head data is essential for definitive comparison.

3. What are the key risks facing ensartinib’s commercial success?
Regulatory delays, safety concerns, adverse trial outcomes, and failure to secure broad reimbursement could all impede market entry and revenue.

4. Which markets present the greatest opportunities for ensartinib?
The U.S., Europe, and Asia, especially Japan and China, where lung cancer prevalence is high and regulatory pathways for oncology drugs are well-established.

5. How might competitive dynamics evolve in the ALK inhibitor space?
Existing drugs are entrenched; however, a new agent demonstrating clear clinical benefits could catalyze market shifts and prompt patent or exclusivity challenges.

---

References

1. Market & Competitive landscape data from Global Data and IQVIA (2022).
2. Clinical trial data from SpringWorks Therapeutics press releases and ClinicalTrials.gov.
3. Regulatory timelines from FDA and EMA guidelines (2023).
4. Pricing benchmarks from Novartis, Pfizer, and AstraZeneca on existing ALK therapies.